BME’s Alternative Fixed-Income Market (MARF) has added the Facephi 2026 Commercial Paper Programme, with a maximum nominal outstanding balance of 20 million euros. Facephi Biometría, S.A., whose shares are listed on BME Growth, will be able to issue euro-denominated promissory notes under the program, with a nominal value of 100,000 euros per note and maturity terms ranging from 3 business days to 730 calendar days. The program will remain in effect for 12 months from the date its base document is listed on the MARF. GVC Gaesco Valores, S.V., S.A. acts as the program’s coordinating entity, agent, and registered advisor. GVC Gaesco Valores and PKF Attest Capital Markets, S.V., S.A. are the collaborating entities. The company has a long-term credit rating of BB- with a stable outlook, assigned by EthiFinance Ratings on July 30, 2026. Facephi Biometría, S.A. is a technology company specializing in digital identity verification, fraud prevention, and regulatory compliance solutions. Its platform, based on artificial intelligence and machine learning, integrates solutions for transaction monitoring, identity verification, authentication and access control, money mule account detection, and behavioral biometrics. The company operates in more than 30 countries. In 2025, the Facephi Group reported revenue of approximately 36 million euros and normalized EBITDA of 10.5 million euros. The MARF now has 166 domestic and international issuers. As of the end of August, it had an outstanding balance of 10,480 million euros, representing a 7.11% increase compared to the same period last year. You can view the schedule and other information about promissory notes accepted on MARF on the BME Exchange website.opens in a new tab
FTSE Mondo Visione Exchanges Index:
BME: MARF Admits The Facephi 2026 Commercial Paper Programme For 20 Million Euros
Date 15/10/2026
